Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
Conditions
Interventions
Placebo
Nemolizumab
Locations
174
United States
Galderma Investigational Site 8880
North Little Rock, Arkansas, United States
Galderma Investigational Site 8578
Cerritos, California, United States
Galderma Investigational Site 8636
Fountain Valley, California, United States
Galderma Investigational Site 8888
Fullerton, California, United States
Galderma Investigational Site 8686
Lomita, California, United States
Galderma Investigational Site 8674
Los Angeles, California, United States
Start Date
June 27, 2019
Primary Completion Date
December 29, 2021
Completion Date
August 11, 2022
Last Updated
August 14, 2024
NCT07321951
NCT03057860
NCT06158490
NCT07344051
NCT05590585
NCT05899816
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions